RPRX · NASDAQ · STOCK
Royalty Pharma (RPRX) Stock Analysis
$56.90
52W $35.23 – $64.38
54/100
$25.24B
23.6
0.41
Is RPRX Bullish or Bearish?
Mixed.
Innellis AI committee rates Royalty Pharma plc (RPRX) Watch with a composite score of 54/100
, based on 5 analysts with 40% agreement.
Last updated October 10, 2026.
What Would Change This View
- Upgrade to Buy
- Requires a committee score of 60.0 — +5.83 from today. Applies on the first day at or above the line; upgrades are never dampened.
- Downgrade to Reduce
- Requires the score to fall below 40.0 — -14.17 from today. The band boundary is 45.0, but a one-step downgrade must clear a further margin first. A score oscillating around the line should not change the rating every night.
Executive Summary
The committee is genuinely divided. Macro Analyst sees a compelling case. Portfolio Manager remains cautious — sector concentration is already high (hhi 2796.97). This disagreement is itself the signal — the setup is not clean in either direction.
Bull & Bear Case
Bull Case
- Dividend yield of 3.0% pays you to wait — Value
- 4 consecutive earnings beats -- consistent execution — Growth
- Quarter-over-quarter growth rate is ACCELERATING, not just positive — Growth
Bear Case
- P/E of 40.2 is expensive by classic value standards — Value
- EPS declining -15.9% YoY despite any revenue growth — Growth
- MACD histogram negative -- bearish momentum — Technical
Both cases are generated from quantitative data signals, not qualitative or
forward-looking judgement. They summarise what the numbers say today.
Price History (6M)
AI Investment Committee
Committee Consensus
As of October 10, 2026
Overall Committee Score
54/100
Agreement
40%
Analysts
5
Conviction
Contested
Sector Rank
Top 70%
of 192 Healthcare peers
Value Analyst
bearish
38
/ 100 · Moderate confidence
Multiples don't clear a genuine value bar here, or cheapness looks justified by weak fundamentals
+ Dividend yield of 3.0% pays you to wait
− P/E of 40.2 is expensive by classic value standards
Growth Analyst
bullish
62
/ 100 · High confidence
Strong, accelerating growth with consistent execution
+ 4 consecutive earnings beats -- consistent execution
− EPS declining -15.9% YoY despite any revenue growth
Technical Analyst
neutral
48
/ 100 · High confidence
Mixed or range-bound price action
− MACD histogram negative -- bearish momentum
Macro Analyst
bullish
65
/ 100 · Low confidence
Macro backdrop is supportive of risk assets generally, and this name's beta works in its favor
News Analyst
neutral
58
/ 100 · Low confidence
News flow is mixed or quiet -- no strong signal either way right now
Portfolio Manager
bearish
30
/ 100 · Moderate confidence
The existing book itself argues for caution here, independent of how good this specific stock looks
− Sector concentration is already high (HHI 2796.97)
Investment Thesis Evolution
Committee score moved marginally from 55.1 to 54.2.
- Conviction changed from moderate to contested.
- Committee agreement fell sharply from 60% to 40%.
- New bearish signals: 1 appeared.
- Bearish pressure eased: 3 signal(s) disappeared.
- Analyst(s) changed stance: News Analyst, Technical Analyst, Value Analyst.
Analyst-level changes:
- News Analyst: stance bullish->neutral; score 62->58 (-5).
- Technical Analyst: stance bearish->neutral; score 38->48 (+10).
- Value Analyst: stance neutral->bearish; score 48->38 (-10); +1 bearish signal(s).
Comparing 2026-10-09 to 2026-10-10 (1 day apart).
Technical Analysis
RSI (14)
40.1
Neutral
MACD Histogram
-0.140
Bearish Momentum
Trend Direction
Sideways
Weekly: Uptrend
Market Structure
Hh Hl
Support
$51.15
Resistance
$64.37
Bollinger %B
0.22
Inside Bands
Price vs Moving Averages
EMA 9
$57.08
Below
EMA 21
$57.93
Below
EMA 50
$58.31
Below
EMA 200
$52.37
Above
Fundamental Analysis
Valuation
44
Growth
74
Profitability
75
Financial Health
50
Cash Flow
70
Valuation
P/E Ratio
23.6×
P/B Ratio
3.71×
PEG Ratio
6.88
Dividend Yield
1.62%
52W High
$64.38
52W Low
$35.23
Quality & Growth
ROE
1190.3%
ROA
392.9%
Gross Margin
8937.8%
Operating Margin
6234.3%
Revenue Growth YoY
—
Debt / Equity
1.31
AI Fundamental Assessment
P/E ratio of 23.6 (inexpensive relative to a 15-40x range); Price-to-book of 3.7x; PEG ratio of 6.9 (under 1.0 suggests growth is undervalued relative to price); Return on equity of 11.9%; Return on assets of 3.9%; Net margin of 32.1%; Gross margin of 89.4%; Current ratio of 1.29 (tight short-term liquidity); Debt-to-equity of 1.31; Free cash flow per share is positive (6.69); Most recent quarter beat estimates by 1.3%; 4 consecutive earnings beats; EPS growth accelerating (-11.6% -> +1.5% QoQ); Analyst estimates falling over recent quarters
Get the Full RPRX Analysis
Interactive charts · Live committee votes · Trade plan · Paper trading · AI Q&A
Open in Terminal →